Is It Time To Reconsider Bio-Rad Laboratories (BIO) After Its Prolonged Share Price Slump

• If you are wondering whether Bio-Rad Laboratories is offering good value at around US$278.44 per share, this article walks through what the current price might be implying about the business.
• The stock has had a mixed run, with a 2.6% gain over the last 7 days, a 7.1% decline over 30 days, an 8.8% decline year to date, a 5.0% return over 1 year, a 44.6% decline over 3 years, and a 51.0% decline over 5 years.
• These ups and downs have kept valuation in focus for many investors, especially as sentiment around life sciences tools and diagnostics companies continues to shift. With no single recent headline dominating the story, it is the longer pattern of share price moves that is raising questions about where fair value might sit now.
• On our framework of 6 valuation checks, Bio-Rad scores 5 out of 6. This puts the spotlight on how different methods like DCFs, multiples and asset based views line up, and it sets us up to look at an even more complete way to think about valuation at the end of this article.

Bio-Rad Laboratories delivered 5.0% returns over the last year. See how this stacks up to the rest of the Life Sciences industry.

Approach 1: Bio-Rad Laboratories Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow model estimates what a company might be worth by projecting its future cash flows and then discounting those back to today, using a required rate of return.

For Bio-Rad Laboratories, the model uses a 2 Stage Free Cash Flow to Equity approach. The latest twelve month free cash flow is about $365.5 million, and the forecast used in the model points to free cash flow of $747.0 million in 2035. Analysts typically provide explicit estimates only for the next few years, so the longer term figures here are extrapolations based on the earlier period.

Putting those projections together, the DCF output suggests an intrinsic value of about $418.03 per share. Compared with the recent share price of around $278.44, this implies the stock is trading at roughly a 33.4% discount to that estimate. On this model, that indicates a meaningful valuation gap.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bio-Rad Laboratories is undervalued by 33.4%. Track this in your watchlist or portfolio, or discover 54 more high quality undervalued stocks.

Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for Bio-Rad Laboratories.

Approach 2: Bio-Rad Laboratories Price vs Earnings

For profitable companies like Bio-Rad Laboratories, the P/E ratio is a useful shorthand for how much investors are paying for each dollar of earnings. It ties the share price directly to the bottom line, which is usually more stable than revenue alone and more relevant than asset values for an operating business.

What counts as a “normal” or “fair” P/E depends on how the market views a company’s growth prospects and risk. Higher growth and lower perceived risk often support a higher P/E, while slower growth or higher uncertainty tend to justify a lower one.

Bio-Rad currently trades on a P/E of 9.89x, compared with the Life Sciences industry average of 33.20x and a peer group average of 49.41x. Simply Wall St’s Fair Ratio for Bio-Rad is 14.41x, which is its proprietary estimate of an appropriate P/E once factors like earnings growth, industry, profit margin, market cap and specific risks are taken into account.

This Fair Ratio can provide a more tailored anchor than a simple comparison with peers or the broad industry, because it adjusts for the company’s own characteristics rather than assuming all Life Sciences stocks deserve the same multiple. Set against the current P/E of 9.89x, the Fair Ratio of 14.41x indicates that the shares are trading below that customised benchmark.

Result: UNDERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Bio-Rad Laboratories Narrative

Earlier we mentioned that there is an even better way to understand valuation, and on Simply Wall St this comes through Narratives. You define the story you believe about Bio-Rad Laboratories, link that story to explicit assumptions for future revenue, earnings and margins, and the platform converts it into a fair value that you can compare with the current share price on the Community page used by millions of investors.

Think of a Narrative as your personal, numbers backed view of the company. Whether you lean toward a higher fair value like US$437.0 or a lower one like US$265.0, the tool then updates automatically as new earnings, news or other data arrive so you can continually see whether your fair value sits above or below the current price and decide for yourself whether that gap is large enough to act on.

Do you think there's more to the story for Bio-Rad Laboratories? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com